Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its ...

When Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge – and that expectation has ...

After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...

The high-profile obesity drug developer priced the biotech sector’s biggest offering since 2022 and will use the proceeds to ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

-- PanGIA Analysis System, a novel machine learning platform for non-invasive diagnosis of oral cancer through an oral sample -- PanGIA Analysis System, a novel machine learning platform for ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force behind this resurgence.

Windlas Biotech approved a Rs 47 crore share buyback at Rs 1,000 per share via the tender route, with April 24 set as the ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

This small biotech could grow much larger with some good news from its pipeline.

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...